{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:49:36Z","timestamp":1786981776100,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>C-X-C motif chemokine receptor 4 (CXCR4)-directed molecular imaging provides excellent read-out capabilities in patients with marginal zone lymphoma (MZL). We aimed to determine the interobserver agreement rate of CXCR4-targeted PET\/CT among readers with different levels of experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>50 subjects with MZL underwent CXCR4-targeted PET\/CT, which were reviewed by four readers (including two experienced and two less experienced observers). The following 8 parameters were investigated: overall scan result, CXCR4 density in lymphoma tissue, extranodal organ involvement, No. of affected extranodal organs and extranodal organ metastases, lymph node (LN) involvement and No. of affected LN areas and LN metastases. We applied intraclass correlation coefficients (ICC;\u2009&lt;\u20090.4, poor; 0.4\u20130.59, fair; 0.6\u20130.74, good and\u2009&gt;\u20090.74 excellent agreement rates).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among all readers, fair agreement was recorded for No. of affected extranodal organs (ICC, 0.40; 95% confidence interval [CI], 0.25\u20130.68), overall scan result (ICC, 0.42; 95%CI, 0.28\u20130.57), CXCR4 density in lymphoma tissue (ICC, 0.52; 95%CI, 0.38\u20130.66), and No. of extranodal organ metastases (ICC, 0.55; 95%CI, 0.41\u20130.61) and LN involvement (ICC, 0.59; 95%CI, 0.46\u20130.71). Good agreement rates were observed for No. of LN metastases (ICC, 0.71; 95%CI, 0.60\u20130.81) and No. of LN areas (ICC, 0.73; 95%CI, 0.63\u20130.82), while extranodal organ involvement (ICC, 0.35; 95%CI, 0.21\u20130.51) achieved poor concordance. On a reader-by-reader comparison, the experienced readers achieved significantly higher agreement rates in 4\/8 (50%) investigated scan items (ICC, range, 0.21\u20130.90, P\u2009&lt;\u2009\/\u2009=\u20090.04). In the remaining 4\/8 (50%), a similar trend with higher ICCs for the experienced readers was recorded (n.s.).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CXCR4-directed PET\/CT mainly provided fair to good agreement rates for scan assessment, while a relevant level of experience seems to be required for an accurate imaging read-out.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11307-024-01940-y","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T12:02:14Z","timestamp":1722513734000},"page":"774-779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interobserver Agreement Rates on CXCR4-Directed PET\/CT in Patients with Marginal Zone Lymphoma"],"prefix":"10.1007","volume":"26","author":[{"given":"Rudolf A.","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Samnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Kosmala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Bundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"1940_CR1","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00432-016-2220-6","volume":"142","author":"S Stollberg","year":"2016","unstructured":"Stollberg S, Kammerer D, Neubauer E, Schulz S, Simonitsch-Klupp I, Kiesewetter B, Raderer M, Lupp A (2016) Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin. J Cancer Res Clin Oncol 142:2239\u20132247","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"1940_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.2967\/jnumed.123.266074","volume":"64","author":"J Duell","year":"2023","unstructured":"Duell J, Buck AK, Hartrampf PE, Schlotelburg W, Schneid S, Weich A, Dreher N, Lapa C, Kircher M, Higuchi T, Samnick S, Serfling SE, Raderer M, Rasche L, Einsele H, Topp MS, Kosmala A, Werner RA (2023) Chemokine Receptor PET\/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma. J Nucl Med 64(12):1889\u201394","journal-title":"J Nucl Med"},{"key":"1940_CR3","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s11307-023-01830-9","volume":"25","author":"A Kosmala","year":"2023","unstructured":"Kosmala A, Seifert S, Schneid S, Dreher N, Higuchi T, Weich A, Serfling SE, Hartrampf PE, Einsele H, Buck AK, Topp MS, Duell J, Werner RA (2023) Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging. Mol Imaging Biol 25:758\u2013764","journal-title":"Mol Imaging Biol"},{"key":"1940_CR4","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.7150\/thno.31032","volume":"9","author":"AR Haug","year":"2019","unstructured":"Haug AR, Leisser A, Wadsak W, Mitterhauser M, Pfaff S, Kropf S, Wester HJ, Hacker M, Hartenbach M, Kiesewetter-Wiederkehr B, Raderer M, Mayerhoefer ME (2019) Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET\/MRI. Theranostics 9:3653\u20133658","journal-title":"Theranostics"},{"key":"1940_CR5","first-page":"1687","volume":"63","author":"AK Buck","year":"2022","unstructured":"Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, Weich A, Pomper MG, Wester HJ, Zehndner A, Schirbel A, Samnick S, Hacker M, Pichler V, Hahner S, Fassnacht M, Einsele H, Serfling SE, Werner RA (2022) Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using (68)Ga-Pentixafor PET. J Nucl Med 63:1687\u20131692","journal-title":"J Nucl Med"},{"key":"1940_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13550-017-0294-z","volume":"7","author":"P Herhaus","year":"2017","unstructured":"Herhaus P, Habringer S, Vag T, Steiger K, Slotta-Huspenina J, Gerngross C, Wiestler B, Wester HJ, Schwaiger M, Keller U (2017) Response assessment with the CXCR4-directed positron emission tomography tracer [(68)Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. EJNMMI Res 7:51","journal-title":"EJNMMI Res"},{"key":"1940_CR7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.120.257279","volume":"62","author":"J Duell","year":"2021","unstructured":"Duell J, Krummenast F, Schirbel A, Klassen P, Samnick S, Rauert-Wunderlich H, Rasche L, Buck AK, Wester HJ, Rosenwald A, Einsele H, Topp MS, Lapa C, Kircher M (2021) Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET\/CT. J Nucl Med 62:1415\u20131421","journal-title":"J Nucl Med"},{"key":"1940_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2967\/jnumed.118.223537","volume":"60","author":"RA Werner","year":"2019","unstructured":"Werner RA, Bundschuh RA, Bundschuh L, Fanti S, Javadi MS, Higuchi T, Weich A, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Herrmann K, Lapa C, Rowe SP (2019) Novel Structured Reporting Systems for Theranostic Radiotracers. J Nucl Med 60:577\u2013584","journal-title":"J Nucl Med"},{"key":"1940_CR9","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2967\/jnumed.117.190827","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Poppel TD, Rischpler C, Schwarzenbock S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M (2017) (68)Ga-PSMA-11 PET\/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med 58:1617\u20131623","journal-title":"J Nucl Med"},{"key":"1940_CR10","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1007\/s00330-023-09518-y","volume":"33","author":"F Grawe","year":"2023","unstructured":"Grawe F, Ebner R, Geyer T, Beyer L, Winkelmann M, Sheikh GT, Eschbach R, Schmid-Tannwald C, Cyran CC, Ricke J, Bartenstein P, Heimer MM, Faggioni L, Spitzweg C, Fabritius MP, Auernhammer CJ, Ruebenthaler J (2023) Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET\/CT and treatment planning in neuroendocrine tumor (NET) patients. Eur Radiol 33:3416\u20133424","journal-title":"Eur Radiol"},{"key":"1940_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/thno.37894","volume":"10","author":"RA Werner","year":"2020","unstructured":"Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, Behr S, Drzezga A, Kimura H, Buck AK, Bengel FM, Pomper MG, Gorin MA, Rowe SP (2020) (18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics 10:1\u201316","journal-title":"Theranostics"},{"key":"1940_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/RLU.0000000000004629","volume":"48","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, Kosmala A, Serfling SE, Bundschuh L, Higuchi T, Lapa C, Rowe SP, Matsusaka Y, Weich A, Buck AK, Bundschuh RA, Werner RA (2023) Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and Therapy. Clin Nucl Med 48:483\u2013488","journal-title":"Clin Nucl Med"},{"key":"1940_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1037\/1040-3590.6.4.284","volume":"6","author":"D Cicchetti","year":"1994","unstructured":"Cicchetti D (1994) Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess 6:284\u2013290","journal-title":"Psychol Assess"},{"key":"1940_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02310555","volume":"16","author":"LJ Cronbach","year":"1951","unstructured":"Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297\u2013334","journal-title":"Psychometrika"},{"key":"1940_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1136\/bmj.314.7080.572","volume":"314","author":"JM Bland","year":"1997","unstructured":"Bland JM, Altman DG (1997) Statistics notes: Cronbach\u2019s alpha. BMJ 314:572","journal-title":"BMJ"},{"key":"1940_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Measur 20:37\u201346","journal-title":"Educ Psychol Measur"},{"key":"1940_CR17","doi-asserted-by":"crossref","unstructured":"Ashby D. (1991) Practical statistics for medical research. Douglas G. Altman, Chapman and Hall, London, 1991. No. of pages: 611. Price: \u00a332.00. Stat Med. 10:1635-1636","DOI":"10.1002\/sim.4780101015"},{"key":"1940_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.114.151647","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, Bluemel C, Keller U, Knop S, Kropf S, Schirbel A, Buck AK, Lassmann M (2015) Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med 56:410\u2013416","journal-title":"J Nucl Med"},{"key":"1940_CR19","doi-asserted-by":"publisher","first-page":"1170394","DOI":"10.3389\/fonc.2023.1170394","volume":"13","author":"A Rivero","year":"2023","unstructured":"Rivero A, Mozas P, Magnano L, Lopez-Guillermo A (2023) Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review. Front Oncol 13:1170394","journal-title":"Front Oncol"},{"key":"1940_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","volume":"84","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T, Pienta KJ, Gafita A, Hope TA, Pomper MG, Eiber M, Gorin MA (2023) Rowe SP. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 84:491\u2013502","journal-title":"Eur Urol"},{"key":"1940_CR21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2967\/jnumed.117.206631","volume":"59","author":"RA Werner","year":"2018","unstructured":"Werner RA, Solnes LB, Javadi MS, Weich A, Gorin MA, Pienta KJ, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C (2018) SSTR-RADS Version 10 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. J Nucl Med. 59:1085\u20131091","journal-title":"J Nucl Med."},{"key":"1940_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M (2023) Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 83:405\u2013412","journal-title":"Eur Urol"},{"key":"1940_CR23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.hoc.2007.06.011","volume":"21","author":"BD Cheson","year":"2007","unstructured":"Cheson BD (2007) The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 21:841\u2013854","journal-title":"Hematol Oncol Clin North Am"},{"key":"1940_CR24","unstructured":"(n.a.) Eckert & Ziegler receives green light for phase III study with PENTIXAFOR.\u00a0Pentixapharm.\u00a0https:\/\/www.pentixapharm.com\/news\/qcqpd2zr93mqysmqsp8ve70mp6za11. Accessed 15 Oct 2023"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01940-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-024-01940-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01940-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T09:10:04Z","timestamp":1727428204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-024-01940-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1007\/s11307-024-01940-y","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"9 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines of the.Declaration of Helsinki. The need for further ethical review and approval were waived.by the local Ethics Committee due to the retrospective character of the study (waiver.no. 20210726 02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all subjects.involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent Statement"}},{"value":"A.K.B. is a member of the advisory board of PentixaPharm. R.A.W. has received speaker honoraria from Novartis\/AAA and PentixaPharm, reports advisory board work for Novartis\/AAA and Bayer, and is involved in [<sup>68<\/sup>\u00a0Ga]Ga-PentixaFor PET Imaging in PAN Cancer (FORPAN), sponsored and planned by PentixaPharm. C.L. is consultant for Blue Earth Diagnostics Ltd. (BED, Oxford, UK) and Novartis (N\u00fcrnberg, Germany). RAB has received speaker\u00b4s honoraria from Bayer Healthcare (Leverkusen, Germany), Novartis (N\u00fcrnberg, Germany) and Eisai GmbH (Frankfurt, Germany) and has received travel expenses from Blue Earth Diagnosis Ltd. (BED, Oxford, UK).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}